Pancreatic Cancer Is Being Caught Earlier Than Ever, Landmark 20-Year Analysis Finds

Pancreatic cancer has long been the most feared diagnosis in oncology, a disease that typically announces itself only after it has already spread beyond hope of surgical cure. Now, one of the largest analyses of its kind suggests that something may finally be changing. A new study drawing on two decades of national cancer registry data finds that the diagnosis of localized pancreatic ductal adenocarcinoma, the earliest and most treatable form of the disease, has been rising steadily in the United States, with a striking acceleration after 2015. The findings, published in Cancer Causes & Control, offer the clearest population-level evidence yet that advances in imaging, endoscopy, and targeted surveillance may be shifting the stage at which this lethal cancer is detected.

The research team, led by Dina Hauptschein, Paul Kang, and Surabhi Amar of the Creighton University Arizona Health Education Alliance, analyzed records from the Surveillance, Epidemiology, and End Results program, the National Cancer Institute’s network of population-based cancer registries. Their final cohort included 227,411 cases of pancreatic ductal adenocarcinoma, or PDAC, diagnosed between 2004 and 2023 across 21 registries covering a substantial portion of the US population. After excluding cases with unknown age, race, or stage, the investigators calculated age-adjusted incidence rates per 100,000 people and used Joinpoint regression, a statistical technique that fits piecewise log-linear models to identify inflection points in disease trends, to estimate how quickly rates were changing over time.

The headline numbers tell a nuanced story. Over the full study period, the age-adjusted incidence of localized PDAC rose with an average annual percent change of 6.00 percent, while distant-stage disease increased only modestly at 1.11 percent per year and regional-stage disease remained essentially flat. Most remarkably, the localized-stage trend accelerated sharply in the latter half of the study period: between 2015 and 2019, the annual percent change in localized diagnoses reached 14.7 percent. Expressed as a share of all staged diagnoses, localized disease climbed from 10.8 percent of cases in 2004 to 19.1 percent in 2023, while distant-stage disease fell from 73.5 percent to 66.4 percent. That is still a sobering majority, but the direction of travel is unmistakable.

Crucially, the trend toward earlier detection was not confined to any single demographic group. Localized-stage incidence rose significantly and comparably in both men and women, with average annual increases of 5.71 percent and 6.29 percent respectively. When the researchers stratified by race and ethnicity, every group showed a significant upward trend in localized diagnoses. Non-Hispanic White individuals saw piecewise annual increases of 14.8 percent between 2015 and 2019, while Non-Hispanic Black individuals experienced similar acceleration of 14.1 percent per year from 2014 to 2019. Hispanic individuals, Non-Hispanic Asian or Pacific Islander individuals, and Non-Hispanic American Indian/Alaska Native individuals all showed significant sustained increases as well, though the latter group displayed greater variability reflecting its smaller population size.

The study also documented persistent and troubling disparities. Non-Hispanic Black individuals had the highest overall incidence of PDAC at 8.91 per 100,000, compared with 7.37 for Non-Hispanic White individuals and 5.38 for Non-Hispanic Asian or Pacific Islander individuals. In multivariable negative binomial regression models adjusting for age, sex, race, and calendar year, Non-Hispanic Black race was associated with a 31 percent higher rate of localized disease and a 43 percent higher rate of distant-stage disease relative to Non-Hispanic White individuals. Prior research has reported pancreatic cancer mortality up to 32 percent higher among Black Americans, and while differences in smoking, obesity, diabetes, healthcare access, and delayed diagnosis likely contribute, the full explanation remains incompletely understood. The new findings underscore that any progress in early detection must grapple with these inequities.

What explains the dramatic post-2015 acceleration in localized diagnoses? The authors point to a convergence of technological and clinical developments. The sheer volume of diagnostic imaging has grown substantially: between 2013 and 2023, the number of CT scans performed in the United States increased by 19.2 percent and MRI scans by 21.4 percent, according to research cited in the study. At the same time, the quality of cross-sectional imaging has improved to the point where smaller pancreatic abnormalities, which would once have escaped notice, are increasingly picked up incidentally during evaluations for unrelated symptoms. Endoscopic ultrasound has also become a routine tool, capable of resolving small lesions and permitting tissue sampling that was previously impractical.

A third driver is the expansion of surveillance programs for people at elevated hereditary risk. Growing recognition of genetic predisposition syndromes involving BRCA1 and BRCA2 mutations, PALB2, Lynch syndrome, hereditary pancreatitis, and familial pancreatic cancer has led to broader implementation of targeted screening using MRI and endoscopic ultrasound in high-risk individuals. Long-term surveillance studies have shown that such programs can detect neoplastic changes before they progress to incurable disease. Meanwhile, researchers are pursuing biomarker-based detection strategies, including protein markers, autoantibodies, circulating tumor DNA, microRNAs, methylated DNA, and exosome-based assays. For patients with pancreatic cysts, cyst-fluid biomarkers such as CEA and mutations in KRAS and GNAS may help risk-stratify potentially precancerous mucinous lesions, though these tests remain adjunctive and require further validation before widespread clinical use.

Yet the authors are careful not to declare victory. The rise in localized diagnoses does not occur in isolation: overall PDAC incidence has also increased across both sexes and all racial and ethnic groups, raising the possibility that at least part of the stage shift reflects a growing underlying disease burden rather than purely earlier detection. Aging populations and the rising prevalence of obesity and diabetes are well-established contributors; according to the CDC’s Behavioral Risk Factor Surveillance System, the percentage of US adults with obesity and diabetes increased by 23 percent and 21 percent respectively between 2011 and 2023. Projections cited in the study suggest pancreatic cancer may become the second-leading cause of cancer-related death in the United States by 2030. More diagnoses of early-stage disease could therefore mean more cancers being found, not fewer cancers progressing.

There is also a methodological caveat that tempers interpretation. Because the SEER database lacks information on screening pathways, individual risk factors, family history, and tobacco use, the study cannot determine why staging patterns changed. More importantly, cases with unknown stage, about 4.7 percent of the identified cases, were excluded from the analysis. If the completeness of staging information improved over the study period, some of the apparent rise in localized incidence could reflect better stage ascertainment rather than a true biological or clinical shift. Changes in staging definitions and reporting practices over two decades could similarly have influenced the results. The authors acknowledge these limitations explicitly and note that the possibility of ascertainment bias cannot be excluded with the available data.

Even with those caveats, the study represents a meaningful milestone in the long struggle against one of medicine’s most stubborn killers. Five-year survival for PDAC remains between 10 and 14 percent, and most patients are still diagnosed with advanced, symptomatic disease. But the demonstration that localized diagnoses are rising across every demographic group, and accelerating in recent years, provides the first population-scale signal that early detection efforts may be gaining traction. Whether that signal translates into longer lives is the critical unanswered question. The authors call for prospective multicenter investigations and randomized trials of targeted screening and surveillance strategies to determine if the growing proportion of localized diagnoses reflects genuine earlier detection, greater diagnostic intensity, an increasing disease burden, or some combination of all three. For a cancer that has defied decades of effort, even a modest, consistent shift in the stage at diagnosis is a development worth watching closely.

Subject of Research: Temporal trends in stage at diagnosis of pancreatic ductal adenocarcinoma in the United States

Article Title: Have we gotten better at diagnosing PDAC before it is too late?: Temporal trends in stage at diagnosis of pancreatic ductal adenocarcinoma in the United States

Article References: Hauptschein, D., Kang, P., & Amar, S. (2026). Have we gotten better at diagnosing PDAC before it is too late?: Temporal trends in stage at diagnosis of pancreatic ductal adenocarcinoma in the United States. Cancer Causes & Control, 37(10), Article 179. https://doi.org/10.1007/s10552-026-02266-6

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02266-6

Keywords: pancreatic cancer, PDAC, early detection, SEER database, cancer staging, incidence trends, endoscopic ultrasound, cancer screening, health disparities, epidemiology, imaging, surveillance